- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07449832
Épigénome du sperme dans le lymphome de Hodgkin (SPELH)
Détection multiparamétrique et approches préventives de l'instabilité épigénétique induite par le traitement du cancer dans la lignée germinale mâle.
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.
We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.
Where possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity.
Here, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tony MARCHAND, MD, PhD
- Numéro de téléphone: +33 02 99 28 42 91
- E-mail: tony.marchand@chu-rennes.fr
Sauvegarde des contacts de l'étude
- Nom: Célia RAVEL, MD, PhD
- Numéro de téléphone: +33 02 99 26 59 16
- E-mail: celia.ravel@chu-rennes.fr
Lieux d'étude
-
-
-
Rennes, France, 35033
- Recrutement
- Centre Hospitalier Universitaire de Rennes
-
Contact:
- Tony MARCHAND, MD, PhD
- Numéro de téléphone: +33 02 99 28 42 91
- E-mail: tony.marchand@chu-rennes.fr
-
Contact:
- Célia RAVEL, MD, PhD
- Numéro de téléphone: +33 02 99 26 59 16
- E-mail: celia.ravel@chu-rennes.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Men aged 18 to 45 years
- Diagnosed with Hodgkin lymphoma
- Treatment-naïve to any cytotoxic therapy
- Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD
- Beneficiaries of the French social security system
- Not opposed to participating in research
Exclusion Criteria:
- Patient receiving abdominal radiotherapy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Epigenetic analysis in semen samples
30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes |
5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Alterations in DNA methylation patterns in spermatozoa
Délai: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Sperm analysis : Methyl-C Capture Sequencing (MCC-seq) |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
|
Alterations of histone 3 H3k4me3 retention sites in spermatozoa
Délai: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq) |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Spermogram exam
Délai: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Spermogram examination |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
|
Identification of known environmental factors impacting spermatogenesis
Délai: Month 24 after chemotherapy
|
Patient questionnaire |
Month 24 after chemotherapy
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Géraldine DELBES, PhD, Institut National de la Recherche Scientifique (INRS), Québec, Canada
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 35RC24_9822_SPELH
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .